Lentiviral Vector-mediated Gene Transfer in Human Bladder Cancer Cell Lines

Anticancer Res. 2018 Apr;38(4):2015-2020. doi: 10.21873/anticanres.12440.

Abstract

Background/aim: Currently, treatment of non-muscle invasive bladder cancer causes significant deterioration in a patient's quality of life (QOL). Therefore, development of novel therapeutic options without the deterioration of QOL is very important. In this study, we assessed the anti-tumor effect of lentivirus-mediated gene transfection of tumor-suppressor genes in human bladder cancer cells.

Materials and methods: Lentiviral vectors that contained the tumor suppressor genes, p53, p16, and PTEN, were transfected into human bladder cancer cell lines, 5637, T24, 253J, and UMUC3, and the normal human uroepithelial cell line, SV-HUC-1.

Results: Significant growth inhibition was observed in bladder cancer cells on transfection with the p16 and PTEN vectors. However, the effect of the p53 vector was limited. In normal cells, the lentiviral vectors did not exhibit a significant growth inhibitory effect.

Conclusion: Lentiviral vector-mediated gene transfection is useful for the application of gene therapy in bladder cancers.

Keywords: Lentivirus; PTEN; bladder cancer; p16; p53.

MeSH terms

  • Cell Line, Tumor
  • Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics
  • Genes, Tumor Suppressor*
  • Genes, p16
  • Genes, p53
  • Genetic Therapy / methods*
  • Genetic Vectors
  • Humans
  • Lentivirus / genetics*
  • Transfection / methods*
  • Tumor Suppressor Protein p53 / biosynthesis
  • Tumor Suppressor Protein p53 / genetics
  • Urinary Bladder Neoplasms / genetics*
  • Urinary Bladder Neoplasms / therapy*
  • Urinary Bladder Neoplasms / virology

Substances

  • CDKN2A protein, human
  • Cyclin-Dependent Kinase Inhibitor p16
  • TP53 protein, human
  • Tumor Suppressor Protein p53